| Autor: |
Kraaijenhof JM; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands (J.M.K., G.K.H., E.S.G.S., N.S.N.)., Opstal TSJ; Department of Cardiology, Radboud University Medical Centre, Nijmegen, the Netherlands (T.S.J.O., J.H.C.).; Department of Cardiology, Northwest Clinics, Alkmaar, the Netherlands (T.S.J.O., J.H.C.)., Cornel JH; Department of Cardiology, Radboud University Medical Centre, Nijmegen, the Netherlands (T.S.J.O., J.H.C.).; Department of Cardiology, Northwest Clinics, Alkmaar, the Netherlands (T.S.J.O., J.H.C.)., Gill D; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, United Kingdom (D.G.)., Hovingh GK; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands (J.M.K., G.K.H., E.S.G.S., N.S.N.)., Catapano AL; Department of Pharmacological and Biomolecular Sciences, University of Milan, Milano, Italy (A.L.C.).; IRCCS Multimedica, Milano, Italy (A.L.C.)., Koenig W; Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (W.K.).; German Centre for Cardiovascular Research (DZHK e.V.), partner site Munich Heart Alliance, Germany (W.K).; Institute of Epidemiology and Medical Biometry, University of Ulm, Germany (W.K.)., Ridker PM; Divisions of Preventive Medicine and Cardiovascular Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (P.M.R.)., Stroes ESG; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands (J.M.K., G.K.H., E.S.G.S., N.S.N.)., Nurmohamed NS; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands (J.M.K., G.K.H., E.S.G.S., N.S.N.).; Department of Cardiology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, The Netherlands (N.S.N.). |
| Jazyk: |
angličtina |
| Zdroj: |
Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2023 Aug; Vol. 43 (8), pp. 1595-1597. Date of Electronic Publication: 2023 Jun 15. |
| DOI: |
10.1161/ATVBAHA.123.319272 |
| Abstrakt: |
Competing Interests: Disclosures J.H. Cornel reports membership on advisory boards for Amgen, Sanofi, Novo Nordisk en AstraZeneca. D. Gill and G.K. Hovingh are employed part-time by Novo Nordisk and own shares. A.L. Catapano reports consulting fees/lecturing fees from Akcea, Amgen, Amryt, Sanofi, Esperion, Kowa, Novartis, Ionis Pharmaceuticals, Mylan, Menarini, Merck, Recordati, Regeneron Daiichi Sankyo, Genzyme, Aegerion, and Sandoz. W. Koenig served on the Executive Steering Committee of SPIRE, which was funded by Pfizer. WK reports advisory board/lecturing fees from Novartis, The Medicines Company, DalCor, Kowa, Amgen, Corvidia, Daiichi-Sankyo, Genentech, Novo Nordisk, Esperion, OMEICOS, Sanofi, New Amsterdam Pharma, TenSixteen Bio and Bristol-Myers Squibb, grants and nonfinancial support from Abbott, Roche Diagnostics, Beckmann, and Singulex, outside the submitted work. Ridker served as the Trial Co-Chair for SPIRE, which was funded by Pfizer. Unrelated to the current project, P.M. Ridker has received additional institutional research grant support from Novartis, Amarin, Pfizer, Esperion, Novo Nordisk, and the NHLBI; has served as a consultant to Novartis, Flame, Agepha, AstraZeneca, Janssen, Civi Biopharm, Glaxo Smith Kline, SOCAR, Novo Nordisk, Uptton, Pfizer, Health Outlook, Montai Health, New Amsterdam, Boehringer-Ingelheim, Angiowave, RTI; Zomagen, Cytokinetics, Horizon Therapeutics, and Cardio Therapeutics; and receives compensation for service on the Peter Munk Advisory Board (University of Toronto), the Leducq Foundation, Paris FR, and the Baim Institute (Boston, MA). ESGS has received lecturing/advisory board fees from Amgen, Novartis, Esperion, Sanofi-Regenerion, and Akcea. NSN is co-founder of Lipid Tools. The other authors report no disclosures. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
